JMJacqueline Magers

Jacqueline Magers

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jacqueline Magers has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Urinary tract infection in the neonatal intensive care unit

    by Jacqueline Magers, Alexandra Burton, Pavel Prusakov, Natalie O. White, Randy R. Miller, Richard Moraille, Anthony R. Theile, Pablo J. Sánchez, Jacqueline K. Magers, Joshua R. Watson, et al.

    Objective: To determine adherence and safety of a diagnostic (culture, urinalysis) and therapeutic (5-day antibiotic course with a time-out) guideline for urinary tract infection (UTI) in the Neonatal Intensive Care Unit Study design: Prospective surveillance of non-bacteremic UTIs from 11/2020-12/2022. Safety outcomes were defined by re-initiation of antibiotics within 7 days for a subsequent UTI due to the same organism and overall and UTI-related mortality. Results: 77 infants received treatment for 93 UTIs with 77% (72/93) adherence to diagnostic criteria; 90% (82/91) of infants received ≤6 days of definitive treatment (median [IQR] antibiotic duration 5 [5–6] days). Antibiotics were restarted within 7 days for a recurrent (same organism) UTI in 1/91 (1%) UTIs. Mortality was 4% (4/93); none were due to UTI. Conclusion: Adherence to diagnostic UTI criteria was 77%. 90% of infants received short course treatment that was associated with a 1% failure rate. No safety concern was identified.

  • Open Access

    1659. Prokinetic Antibiotic Agents in the Neonatal Intensive Care Unit: Ripe for Antibiotic Stewardship Efforts!

    by Jacqueline Magers, Pavel Prusakov, Michael Storey, Pablo J J Sanchez

    Intolerance to enteral nutrition among infants in the neonatal intensive care unit (NICU) may lead to the use of prokinetic agents to improve gastric emptying and feeding tolerance. Two such oral prokinetic agents are erythromycin and amoxicillin-clavulanate that have been used in cases of dysmotility due to intestinal failure. However, dosing strategies vary and the recommended duration of therapy has not been determined. Moreover, the use of these oral antibiotics in the NICU may fall under the radar of neonatal antimicrobial stewardship programs. Our objective was to quantify their use in the Level 4 outborn NICU at Nationwide Children’s Hospital, Columbus, OH in order to inform antibiotic stewardship efforts. This was a retrospective cohort study of all infants who received enteral erythromycin or amoxicillin-clavulanate in the NICU. The number of doses of each antibiotic was obtained from the Nationwide Children’s Hospital Pharmacy database. Pertinent clinical, laboratory, and outcome data were obtained. From January 1, 2022 to April 30, 2023, 15 infants in the NICU received ≥1 dose of erythromycin ethylsuccinate and 19 infants received ≥1 dose of amoxicillin-clavulanate enterally. Erythromycin was always used to improve motility while amoxicillin-clavulanate served as a prokinetic agent in 53% of infants in whom it was prescribed. Demographics and reason for initiation are provided in Table 1. The median (IQR) doses per patient for erythromycin was 64 (28, 125; dosing interval varied from every 6 to every 8 hours) and for amoxicillin-clavulanate was 50 (9, 105) doses per patient (majority of doses were given on a BID schedule). Enteral erythromycin and amoxicillin-clavulanate have not been the target of antimicrobial stewardship programs. These antibiotics may contribute to dysbiosis and adverse events in NICU infants. An automatic stop time with a time-out when ordered in the electronic health record may be a viable strategy to reduce overutilization of these antibiotics. Pavel Prusakov, PharmD, Merck & Co: Grant/Research Support|Merck & Co: Employee Michael Storey, PharmD, MS, CSL Behring: Advisor/Consultant|Sarepta Therapeutics: Advisor/Consultant

  • Short-course antibiotic therapy for pneumonia in the neonatal intensive care unit

    by Zachery S. Lewald, Pavel Prusakov, Jacqueline K. Magers, Matthew J. Kielt, Concepción de Alba Romero, Natalie O. White, Randy R. Miller, Richard Moraille, Anthony R. Theile, Pablo J. Sánchez, et al.

    Objective To determine the adherence and safety outcomes of a 5-day antibiotic course with a “time-out” for treatment of “blood culture-negative” pneumonia in the NICU. Study design Prospective surveillance of all infants diagnosed with pneumonia at 7 NICUs from 8/2020-12/2021. Safety outcomes were defined a priori by re-initiation of antibiotic therapy within 14 days after discontinuation and overall and sepsis-related mortality. Results 128 infants were diagnosed with 136 episodes of pneumonia; 88% (n = 119) were treated with 5 days of definitive antibiotic therapy. Antibiotics were restarted within 14 days in 22 (16%) of the 136 pneumonia episodes. However, only 3 (3%) of the 119 episodes of pneumonia treated for 5 days had antibiotics restarted for pneumonia. Mortality was 5% (7/128); 5 of the 7 deaths were assessed as sepsis-related. Conclusion Adherence to the 5-day definitive antibiotic treatment for “culture-negative” pneumonia was high and the intervention seemed safe.


  • Open Access

    Short-Course Antibiotic Therapy for Pneumonia in the Neonatal Intensive Care Unit

    by Pablo Sanchez, Zachery Lewald, Pavel Prusakov, Jacqueline Magers, Matthew Kielt, Concepcion de Alba Romero, Natalie White, Randy Miller, Richard Moraille, Anthony Thiele

    Objective. To determine the adherence and safety outcomes of a 5-day antibiotic course with a “time-out” for treatment of “blood culture-negative” pneumonia in the NICU Study design. Prospective surveillance of all infants diagnosed with pneumonia at 7 NICUs from 8/2020-12/2021. Safety outcomes were defined a priori by re-initiation of antibiotic therapy within 14 days after discontinuation and overall and sepsis-related mortality. Results. 128 infants were diagnosed with 136 episodes of pneumonia; 88% (n=119) were treated with 5 days of definitive antibiotic therapy. Antibiotics were restarted within 14 days in 22 (16%) of the 136 pneumonia episodes. Mortality was 5% (7/128); 5 of the 7 deaths were assessed as sepsis-related. There was no difference in the combined safety outcomes of antibiotic restart or mortality between ≤5 and 6-20 days of definitive antibiotic treatment. Conclusion. Adherence to the 5-day definitive antibiotic treatment for “culture-negative” pneumonia was high and the intervention seemed safe.

  • Short-course empiric antibiotic therapy for possible early-onset sepsis in the NICU

    by Pablo J. Sánchez, Pavel Prusakov, Concepción de Alba Romero, Elena Zamora-Flores, María Camila Reyes Escamilla, Natalie O. White, Randy R. Miller, Richard Moraille, Anthony R. Theile, Jacqueline K. Magers, et al.

    Objective On 2/2019, the Neonatal Antimicrobial Stewardship Program at Nationwide Children’s Hospital recommended reducing empirical antibiotic therapy for early-onset sepsis (EOS) from 48 to 24 hours with a TIME-OUT. We describe our experience with this guideline and assess its safety. Methods Retrospective review of newborns evaluated for possible EOS at 6 NICUs from 12/2018-7/2019. Safety endpoints were re-initiation of antibiotics within 7 days after discontinuation of the initial course, positive bacterial blood or cerebrospinal fluid culture in the 7 days after antibiotic discontinuation, and overall and sepsis-related mortality. Result Among 414 newborns evaluated for EOS, 196 (47%) received a 24 hour rule-out sepsis antibiotic course while 218 (53%) were managed with a 48 hour course. The 24-hour rule-out group were less likely to have antibiotics re-initiated and did not differ in the other predefined safety endpoints. Conclusion Antibiotic therapy for suspected EOS may be discontinued safely within 24 hours.


  • Open Access

    Short-Course Empiric Antibiotic Therapy for Possible Early-Onset Sepsis in the NICU

    by Pablo Sanchez, Pavel Prusakov, Concepcion de Alba Romero, Elena Zamora-Flores, María Reyes Escamilla, Natalie White, Randy Miller, Richard Moraille, Anthony Thiele, Jacqueline Magers

    Objective. On 2/2019, the Neonatal Antimicrobial Stewardship Program at Nationwide Children’s Hospital recommended reducing empirical antibiotic therapy for early-onset sepsis (EOS) from 48 to 24 hours with a TIME-OUT. We describe our experience with this guideline and assess its safety. Methods. Retrospective review of all newborns evaluated for possible EOS at Result. Among 414 newborns evaluated for EOS, 196 (47%) received a 24 hour rule-out sepsis antibiotic course while 218 (53%) were managed with a 48 hour course. Infants in the two groups did not differ in the predefined safety endpoints. Conclusion. Antibiotic therapy for suspected EOS may be discontinued safely within 24 hours.

  • Effects of prophylactic indomethacin on intraventricular hemorrhage and adverse outcomes in neonatal intensive care unit

    by Colleen J. Miller, Pavel Prusakov, Jacqueline Magers, Sunday Speaks, Hana Sacic, Kelsi Escobar, Mahmoud Abdel-Rasoul, Leif D. Nelin

    Objective To identify the relationship between prophylactic indomethacin (PI) administration and incidence of intraventricular hemorrhage. Study design A retrospective analysis of extremely premature infants p = 0.68). The rate of rise of serum creatinine from baseline to day of life four was significantly higher in the PI group (0.14 mg/dl PI and 0.03 mg/dl control, p < 0.001). Conclusion PI was not associated with any benefit in prevention of IVH, but is associated with adverse effects including acute rise in creatinine.